Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Barclays PLC

Barclays PLC reduced its holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 85.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,156 shares of the biopharmaceutical company's stock after selling 105,306 shares during the period. Barclays PLC owned about 0.15% of Corbus Pharmaceuticals worth $215,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in CRBP. Wells Fargo & Company MN lifted its stake in shares of Corbus Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 2,195 shares during the period. Avanza Fonder AB acquired a new position in shares of Corbus Pharmaceuticals in the 4th quarter valued at $84,000. JPMorgan Chase & Co. lifted its stake in shares of Corbus Pharmaceuticals by 27.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock valued at $114,000 after purchasing an additional 1,172 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Corbus Pharmaceuticals by 4.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 97,882 shares of the biopharmaceutical company's stock valued at $1,155,000 after purchasing an additional 4,239 shares during the period. Finally, HealthInvest Partners AB lifted its stake in shares of Corbus Pharmaceuticals by 41.3% in the 4th quarter. HealthInvest Partners AB now owns 98,304 shares of the biopharmaceutical company's stock valued at $1,188,000 after purchasing an additional 28,731 shares during the period. 64.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CRBP has been the subject of a number of research analyst reports. HC Wainwright reduced their price objective on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. B. Riley restated a "buy" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, May 7th. Oppenheimer reduced their price objective on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Wedbush restated an "outperform" rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. Finally, Jefferies Financial Group reduced their target price on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $50.88.

Corbus Pharmaceuticals Stock Up 2.4%

CRBP stock traded up $0.17 during mid-day trading on Thursday, hitting $7.21. 59,996 shares of the company were exchanged, compared to its average volume of 358,594. The firm has a market capitalization of $88.23 million, a P/E ratio of -1.54 and a beta of 3.19. Corbus Pharmaceuticals Holdings, Inc. has a 12-month low of $4.64 and a 12-month high of $61.90. The business has a fifty day simple moving average of $6.34 and a 200-day simple moving average of $10.66.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.13). Research analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 EPS for the current year.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.